Tharimmune, Inc. (THAR) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Bridgewater, NJ, United States. The current CEO is Mark Wendland.
THAR has IPO date of 2022-01-12, 2 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $134.01M.
Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.
